title: Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
abstract: The aim of any anticancer treatment is to avoid, control, or eliminate disseminated tumor cells. Clinical and experimental evidence has revealed that metastases can remain in a latency state, that is, metastasis dormancy. Three mechanisms are thought to be involved in cancer dormancy: cellular dormancy, angiogenic dormancy, and immune-mediated dormancy. Here, we review the mechanisms and cells involved in immune-mediated cancer dormancy and discuss current and future immunotherapeutic strategies. Recent results indicate that the immune system can restrain disseminated cancer cells, promoting their permanent dormancy. CD8(+) T lymphocytes play a relevant role in maintaining immune equilibrium with metastatic dormant cells, and MHC class I surface expression on tumor cells may also be involved. Natural killer (NK) cells have an activator function that triggers a cytotoxic T lymphocyte (CTL) response. Furthermore, immune dormancy promotes cancer cell growth arrest and angiogenic control. Immunotherapeutic interventions in metastatic dormancy may help to control or eradicate cancer disease. Treatments that activate or increase the CTL immune response or reverse cancer cell-induced CTL immunosuppression might be useful to restrain or destroy metastatic cells. These objectives may be achieved by recovering or increasing MHC class I surface expression on cancer cells or even by activating NK cells. Immune-mediated metastasis dormancy provides an opportunity for targeting cancer in novel immune treatments.
authors.affiliation: Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico Hospital Universitario Virgen de las Nieves, Granada, Spain. Instituto de Investigación Biosanitaria ibs., Granada, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Romero
authors.affiliation: Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico Hospital Universitario Virgen de las Nieves, Granada, Spain. Instituto de Investigación Biosanitaria ibs., Granada, Spain. Departamento de Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Garrido
authors.affiliation: Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico Hospital Universitario Virgen de las Nieves, Granada, Spain. Instituto de Investigación Biosanitaria ibs., Granada, Spain. angel.miguel.exts@juntadeandalucia.es.
authors.forename: Angel M
authors.initials: AM
authors.lastname: Garcia-Lora
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D009362:Neoplasm Metastasis / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology